AxoGen, a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, today announced approval by the Rizzoli Orthopaedic Institute of its first commercial shipment of Avance® Nerve Graft to MD for Life, its new distribution partner in Italy. Avance Nerve Graft is a processed nerve allograft for bridging nerve discontinuities (gaps created when nerves are severed). By eliminating a second surgery to harvest the patient’s own nerve tissue for use in the repair, Avance Nerve Graft offers an alternative to traditional autograft nerve repair procedures.
The Rizzoli Orthopaedic Institute is Italy’s largest tissue bank and handles review and approval of all donors of AxoGen processed nerve allograft tissue to assure quality.
“Our ongoing partnership with the prestigious Rizzoli Orthopaedic Institute underscores the quality of AxoGen’s tissue processing and confirms the growing demand for Avance Nerve Graft in markets outside of the United States,” said Karen Zaderej, AxoGen’s Chief Executive Officer. “AxoGen is committed to providing innovative technologies of the highest standards to surgeons worldwide for the treatment and reconstruction of injured peripheral nerves.”
To date, thousands of patients who have suffered traumatic injuries have been surgically implanted with AxoGen’s products. In addition to Avance Nerve Graft, the Company’s portfolio of products and technologies include AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.